Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases
Individuals suffering with rare diseases had very few therapeutic options 40 years ago. But that began to change with the stroke of a pen by then-President Ronald Reagan in January 1983 when he signed the bipartisan Orphan Drug Act into law. On Jan. 4, the rare disease community will celebrate the 40th anniversary of the Orphan Drug Act (ODA) — legislation that incentivized drug companies to put more resources toward the research, development, and distribution of therapeutics for people with rare diseases, who until then had been ‘orphaned’ by the medical and scientific community.
The creation of the ODA and the founding of the National Organization for Rare Disorders (NORD) are forever intertwined. The rare patients and caregivers who started the rare advocacy movement — which convinced lawmakers to introduce orphan drug legislation — knew their work was not done after the bill became law. They formed NORD to unify the voices of the unheard within the rare disease community under the premise that a rising tide could lift all boats.
myBinderRelated Content
-
AA AmyloidosisAA amyloidosis, or secondary amyloidosis...
-
Michael Alan Rosenzweig, MD, MSMichael Alan Rosenzweig is an Associate ...
-
Identification of Prognostic Markers in Transthyretin and AL Cardiac AmyloidosisBackground: The prognosis of amyloidosi...
-
Multiple Myeloma and Amyloidosis Program, Cedars-SinaiThe Multiple Myeloma and Amyloidosis pro...
-
A Guide to Transthyretin AmyloidosisAmyloidosis is a systemic disorder chara...
-
Marked Progress in AL Amyloidosis Survival: A 40-Year Longitudinal Natural History StudyThe recent decades have ushered in consi...
-
Rafat Abonour, MDRafat Abonour is a Professor in the Depa...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
